Dario Campana

Q: What Schools Are Affiliated With Dario Campana

Dario Campana is affiliated with the following schools: Hiroshima University, University College London, National University of Singapore, University of Chicago, Johns Hopkins University, University of Tennessee Health Science Center, University of Helsinki

Dario Campana's AcademicInfluence.com Rankings

Dario Campana

Philosophy

#6352

World Rank

#9377

Historical Rank

Logic

#3528

World Rank

#4706

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Dario Campana Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dario Campana's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. (2002) (1998)
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia (2012) (1437)
Treating childhood acute lymphoblastic leukemia without cranial irradiation. (2009) (1051)
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. (2009) (1048)
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. (2009) (985)
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. (2009) (790)
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia (2004) (661)
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. (2005) (551)
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. (2009) (505)
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. (2010) (475)
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. (2004) (467)
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. (2000) (461)
Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia (1998) (460)
Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. (1995) (448)
NK cells for cancer immunotherapy (2020) (398)
Primary B cell immunodeficiencies: comparisons and contrasts. (2009) (374)
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. (2004) (372)
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. (2012) (365)
An essential role for BLNK in human B cell development. (1999) (331)
New markers for minimal residual disease detection in acute lymphoblastic leukemia. (2011) (302)
Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia (2009) (279)
Childhood acute lymphoblastic leukaemia--current status and future perspectives. (2001) (268)
Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia (1993) (268)
Minimal residual disease in acute lymphoblastic leukemia. (2010) (268)
Mutations in the Human λ5/14.1 Gene Result in B Cell Deficiency and Agammaglobulinemia (1998) (267)
Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. (2002) (266)
Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. (1992) (260)
A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. (2013) (248)
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. (2007) (244)
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia (2011) (244)
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. (2012) (241)
Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. (1996) (230)
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. (2014) (220)
Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. (1996) (217)
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. (2004) (209)
Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors (2010) (206)
PITSLRE protein kinase activity is associated with apoptosis (1995) (204)
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital (2000) (203)
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. (2005) (200)
Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue. (1985) (198)
Mutations in Igα (CD79a) result in a complete block in B-cell development (1999) (186)
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. (2009) (184)
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. (2012) (179)
The immunologic detection of minimal residual disease in acute leukemia. (1990) (179)
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. (2012) (173)
2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells (2009) (172)
The cytoplasmic expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage. (1987) (171)
Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. (2002) (170)
Detection of minimal residual disease in acute leukemia by flow cytometry. (1999) (168)
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. (1985) (166)
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. (2012) (164)
A novel monoclonal antibody BI-3C5 recognises myeloblasts and non-B non-T lymphoblasts in acute leukaemias and CGL blast crises, and reacts with immature cells in normal bone marrow. (1985) (164)
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. (2009) (161)
Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. (1994) (160)
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. (2015) (159)
Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. (2001) (158)
Ligation of CD38 suppresses human B lymphopoiesis (1995) (158)
Immunophenotyping of leukemia. (2000) (154)
Determination of minimal residual disease in leukaemia patients (2003) (154)
Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia (2004) (153)
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. (2019) (153)
Phenotypic features and proliferative activity of B cell progenitors in X-linked agammaglobulinemia. (1990) (151)
T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. (2014) (147)
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. (2011) (146)
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. (2010) (143)
Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. (1993) (143)
New definition of remission in childhood acute lymphoblastic leukemia (2000) (140)
A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. (2012) (140)
Clinical significance of early T‐cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children’s Cancer Study Group Study L99‐15 (2012) (136)
The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases. (1989) (135)
Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients (2015) (133)
Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method (2010) (131)
Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase (2003) (130)
Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia (2003) (128)
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. (2007) (128)
Improved prognosis for older adolescents with acute lymphoblastic leukemia. (2010) (127)
Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. (1996) (126)
Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. (1996) (126)
Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1 (2009) (125)
Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. (2011) (124)
Clinical Impact of Minimal Residual Disease in Children with Different Subtypes of Acute Lymphoblastic Leukemia Treated with Response-Adapted Therapy (2016) (124)
A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. (2006) (122)
Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104 (2011) (120)
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. (2011) (120)
The expression of T cell receptor-associated proteins during T cell ontogeny in man. (1989) (119)
Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real‐time PCR (2005) (118)
IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. (1998) (117)
Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. (2014) (117)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse (2004) (117)
Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. (2019) (116)
ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy (2012) (114)
Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. (2012) (111)
Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. (2009) (109)
A Revised Definition for Cure of Childhood Acute Lymphoblastic Leukemia (2014) (109)
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. (2012) (106)
Childhood acute lymphoblastic leukemia. (2007) (106)
Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia (1999) (105)
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. (2006) (101)
CD38 signal transduction in human B cell precursors. Rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C-gamma and phosphatidylinositol 3-kinase. (1996) (99)
Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia. (2017) (99)
Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group. (2009) (99)
Expansion and activation of natural killer cells for cancer immunotherapy. (2009) (97)
Detection of minimal residual disease in pediatric acute lymphoblastic leukemia (2013) (97)
Minimal residual disease monitoring in childhood acute lymphoblastic leukemia (2012) (96)
Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. (1999) (96)
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy (2012) (95)
Hyper IgM syndrome associated with defective CD40-mediated B cell activation. (1994) (92)
X‐Linked Agammaglobulinemia: New Approaches to Old Questions based on the Identification of the Defective Gene (1994) (90)
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. (2012) (90)
Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation (2013) (87)
Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. (2017) (87)
Replicative potential of human natural killer cells (2009) (85)
Minimal Residual Disease Studies by Flow Cytometry in Acute Leukemia (2004) (85)
Idiopathic Myelofibrosis: a Possible Role for Immune‐Complexes in the Pathogenesis of Bone Marrow Fibrosis (1981) (85)
Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. (1994) (84)
Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. (2002) (83)
Prognostic factors in the acute lymphoid and myeloid leukemias of infants. (1996) (83)
Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. (1998) (81)
Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. (2005) (79)
Double and triple staining methods for studying the proliferative activity of human B and T lymphoid cells. (1988) (78)
A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus (2013) (77)
CD38-mediated growth suppression of B-cell progenitors requires activation of phosphatidylinositol 3-kinase and involves its association with the protein product of the c-cbl proto-oncogene. (1996) (75)
Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. (1991) (74)
The immunophenotype of T‐lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report (2012) (74)
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma (2016) (74)
Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. (2015) (74)
Status of minimal residual disease testing in childhood haematological malignancies (2008) (73)
Rearrangement of immunoglobulin and T cell antigen receptor genes in acute myeloid leukemia with lymphoid-associated markers. (1987) (69)
Cytotoxicity of the anti‐CD22 immunotoxin HA22 (CAT‐8015) against paediatric acute lymphoblastic leukaemia (2010) (69)
Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. (2011) (68)
The detection of residual acute lymphoblastic leukemia cells with immunologic methods and polymerase chain reaction: a comparative study. (1990) (67)
Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity (2010) (66)
Minimal residual disease monitoring by flow cytometry. (2003) (66)
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome‐positive acute lymphoblastic leukemia (2014) (65)
Mutations in Igalpha (CD79a) result in a complete block in B-cell development. (1999) (64)
Effect of body mass index on the outcome of children with acute myeloid leukemia (2012) (63)
Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study (2009) (61)
Lineage relationship of chronic lymphocytic leukemia and hairy cell leukemia: studies with TPA. (1984) (60)
CD38 ligation in human B cell progenitors triggers tyrosine phosphorylation of CD19 and association of CD19 with lyn and phosphatidylinositol 3-kinase. (1997) (60)
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. (2017) (60)
Synthetic messenger RNA as a tool for gene therapy. (2006) (59)
N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. (1993) (58)
Expanded and armed natural killer cells for cancer treatment. (2016) (58)
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. (2011) (55)
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing (2015) (55)
Leukemia diagnosis and testing of complement-fixing antibodies for bone marrow purging in acute lymphoid leukemia. (1986) (55)
The definition of remission in acute leukemia with immunologic techniques. (1991) (53)
Progress of Minimal Residual Disease Studies in Childhood Acute Leukemia (2010) (52)
Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St. Jude AML97 Trial (2009) (52)
Universal monitoring of minimal residual disease in acute myeloid leukemia. (2018) (51)
Expression and Activation of the Nonreceptor Tyrosine Kinase Tec in Human B Cells (1998) (51)
Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. (2007) (50)
Prevalence and growth characteristics of malignant stem cells in B-lineage acute lymphoblastic leukemia. (1997) (49)
Phenotypic, genotypic, cytochemical, and ultrastructural characterization of acute undifferentiated leukemia. (1990) (49)
Detection of minimal residual disease in acute lymphoblastic leukemia: the St Jude experience (2001) (49)
Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer (2014) (46)
Genetic Variants in Cytosolic 5′-Nucleotidase II Are Associated with Its Expression and Cytarabine Sensitivity in HapMap Cell Lines and in Patients with Acute Myeloid Leukemia (2011) (46)
Minimal residual disease quantitation in acute myeloid leukemia. (2009) (46)
Molecular interactions between human B-cell progenitors and the bone marrow microenvironment. (1996) (46)
Stroma-supported immunocytometric assay (SIA): a novel method for testing the sensitivity of acute lymphoblastic leukemia cells to cytotoxic drugs. (1993) (45)
Applications of cytometry to study acute leukemia: in vitro determination of drug sensitivity and detection of minimal residual disease. (1994) (44)
A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. (2018) (44)
Natural killer cell engineering for cellular therapy of cancer. (2011) (44)
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia (2013) (44)
T lymphocyte regeneration after transplantation of T cell depleted allogeneic bone marrow. (1986) (43)
4-1BB Chimeric Antigen Receptors (2014) (43)
Molecular determinants of treatment response in acute lymphoblastic leukemia. (2008) (43)
Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children’s Oncology Group Study POG 9421 (2013) (41)
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. (2013) (40)
Human leukocyte function‐associated antigens on lympho‐hemopoietic precursor cells (1986) (39)
Minimal residual disease studies in acute leukemia. (2004) (39)
Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study (2009) (37)
Minimal residual disease in acute lymphoblastic leukemia. (2009) (36)
CD38 in hematopoiesis. (2000) (35)
Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. (2021) (35)
CD38-mediated signaling events in murine pro-B cells expressing human CD38 with or without its cytoplasmic domain. (1999) (35)
Rapid down‐regulation of protein kinase C and membrane association in phorbol ester‐treated leukemia cells (1985) (35)
Proliferation of normal and malignant human immature lymphoid cells (1988) (35)
Should evaluation for minimal residual disease be routine in acute myeloid leukemia? (2013) (34)
Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. I. Cytotoxicity of interferon alpha in acute lymphoblastic leukemia. (1993) (34)
Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing. (2010) (33)
CD38 ligation inhibits normal and leukemic myelopoiesis. (2000) (33)
Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. (2006) (33)
Treatment outcome in older patients with childhood acute myeloid leukemia (2012) (32)
Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. (1998) (31)
Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (2011) (31)
Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy (2015) (31)
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. (2011) (31)
In vitro cytotoxicity of docetaxel in childhood acute leukemias. (1998) (30)
Age-related differences in leukemia biology and prognosis: the paradigm of MLL-AF4-positive acute lymphoblastic leukemia (2007) (30)
Phase I study of cytokine-gene modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma. (1992) (30)
Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia (2013) (30)
Reduced-dose-intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study. (2020) (30)
Expression of T-cell receptors TcR1 (gamma/delta) and TcR2 (alpha/beta) in the human intestinal mucosa. (1989) (29)
Cyclosporin A Induces Apoptosis in Childhood Acute Lymphoblastic Leukemia Cells (1998) (29)
Kinetics of T lymphocyte development. (1989) (29)
Expression and activation of the nonreceptor tyrosine kinase Tec in human B cells. (1998) (27)
DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIAS: METHODOLOGICAL ADVANCES AND CLINICAL SIGNIF-ICANCE (1995) (27)
Autologous bone marrow transplantation in acute lymphoblastic leukemia--preclinical immunologic studies. (1988) (27)
Development of a regional flow cytometry center for diagnosis of childhood leukemia in Central America (2005) (26)
Expression of the adaptor protein BLNK/SLP-65 in childhood acute lymphoblastic leukemia (2004) (26)
Correlation of immunophenotype with rearrangement of T cell antigen receptor beta and gamma genes in acute lymphoblastic leukemia of adults. (1988) (26)
Stromal cell-mediated transcriptional regulation of the CD13/aminopeptidase N gene in leukemic cells. (1995) (25)
Chimeric antigen receptor-T cells with cytokine neutralizing capacity. (2020) (25)
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. (2013) (24)
The effect of body mass index at diagnosis on clinical outcome in children with newly diagnosed acute lymphoblastic leukemia (2017) (24)
Simple methods for the rapid exchange of flow cytometric data between remote centers (2000) (23)
Treatment of Childhood Acute Lymphoblastic Leukaemia (1988) (23)
Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. II. Potent cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemia. (1994) (23)
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers (2020) (23)
Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells. (2001) (22)
Should Minimal Residual Disease Monitoring in Acute Lymphoblastic Leukemia be Standard of Care? (2012) (21)
Human B-cell progenitors and bone marrow microenvironment. (1996) (21)
Reverse‐engineering flow‐cytometry gating strategies for phenotypic labelling and high‐performance cell sorting (2018) (21)
Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion (2016) (20)
Natural killer cell reprogramming with chimeric immune receptors. (2013) (20)
Atypical Wiskott-Aldrich syndrome in a girl (1992) (20)
Proliferation of normal and malignant human immature lymphoid cells. (1988) (20)
Fas activates NF-κB and induces apoptosis in T-cell lines by signaling pathways distinct from those induced by TNF-α (1997) (19)
Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse (2008) (19)
Detection of residual leukemia with immunologic methods: technical developments and clinical implications. (1994) (18)
B‐chronic lymphocytic leukaemia patients with stable benign disease show a distinctive membrane phenotype (1984) (18)
Measurements of treatment response in childhood acute leukemia (2012) (18)
Multiple chromosome abnormalities in a drug resistant TdT positive B-cell leukemia. (1987) (17)
ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells. (2005) (17)
Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. (2010) (17)
A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus. (2013) (17)
Atypical Wiskott-Aldrich syndrome in a girl. (1992) (17)
The antifungal antibiotic clotrimazole alters calcium homeostasis of leukemic lymphoblasts and induces apoptosis (2002) (17)
Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies (2012) (17)
Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes. (2017) (16)
Recombinant interleukin 2 and anti-Tac influence the growth of enriched multipotent hemopoietic progenitors: proposed hypotheses for different responses in early and late progenitors. (1988) (16)
Toward a clinically useful classification of the acute leukemias. (1995) (16)
Minimal Residual Disease–Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial. (2009) (15)
Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study (2011) (15)
Karyotype and T‐cell receptor expression in t‐lineage acute lymphoblastic leukemia (1992) (15)
Growth requirements of normal and leukemic human B cell progenitors. (1994) (14)
Genetic modification of T cells for cancer therapy. (2004) (13)
Variable corticosteroid sensitivity of thymic cortex and medullary peripheral-type lymphoid tissue in myasthenia gravis patients: structural and functional effects. (1989) (12)
Monitoring minimal residual disease in acute leukemia: expectations, possibilities and initial clinical results (1994) (12)
Characterization of CD34+, CD13+, CD33- cells, a rare subset of immature human hematopoietic cells. (2002) (12)
Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude Children's Research Hospital from 1962 to 2002. (2013) (12)
Characterization of normal and regenerating bone marrow cells with a panel of monoclonal antibodies. (2009) (11)
Definition of cure in childhood acute myeloid leukemia (2014) (11)
A new method for high speed, sensitive detection of minimal residual disease (2012) (11)
Mutations in Ig α ( CD 79 a ) result in a complete block in B-cell development (11)
Signals mediated by FcγRIIA suppress the growth of B-lineage acute lymphoblastic leukemia cells (2002) (11)
Minimal residual disease. (2012) (10)
Growth requirements and immunophenotype of acute lymphoblastic leukemia progenitors. (2005) (10)
Signals mediated by FcgammaRIIA suppress the growth of B-lineage acute lymphoblastic leukemia cells. (2002) (10)
Integrated Analysis of Pharmacokinetic, Clinical, and SNP Microarray Data Using Projection onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing (2009) (10)
Improved Remission Induction Rate of Childhood AML: Preliminary Results of the AML02 Trial. (2005) (9)
"Cytoplasmic" expression of nuclear antigens. (1989) (9)
Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia (2013) (8)
The use of flow cytometry to detect minimal residual disease in acute leukemia. (1996) (8)
4 Immunophenotyping in haematological diagnosis (1990) (8)
Lack of constitutive activation of Janus kinases and signal transduction and activation of transcription factors in Philadelphia chromosome-positive acute lymphoblastic leukemia. (1996) (8)
Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients (2012) (8)
Children's Research Hospital Acute mixed lineage leukemia in children: the experience of St Jude (2012) (8)
Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Down Syndrome Acute Myeloid Leukemia (DS-AML): Results of the Children’s Oncology Group (COG) Phase III AAML0431 Trial (2014) (7)
Phenotypic changes and proliferative activity of human gamma delta T cell receptor-bearing cells upon activation. (1991) (7)
A possible pathogenetic role of cationic proteins (CP) released by stored granulocytes in the development of pulmonary infiltrates after granulocyte transfusions. (2009) (7)
Minimal residual disease detection in acute lymphoblastic leukemia: real improvement with the real-time quantitative PCR method? (2003) (7)
Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431. (2019) (7)
EARLY T-CELL PRECURSOR LEUKEMIA: A SUBTYPE OF VERY HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA IDENTIFIED IN TWO INDEPENDENT COHORTS (2010) (6)
Functional behaviour and immunological phenotype of circulating B lymphocytes in multiple myeloma. Studies with pokeweed mitogen. (1984) (6)
Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy. (2019) (6)
Ex Vivo Activated Natural Killer (NK) Cells from Myeloma Patients Kill Autologous Myeloma and Killing Is Enhanced by Elotuzumab (2008) (5)
Minimal residual disease in pediatric ALL (2017) (5)
Immune-complexes and antiplatelet antibodies in idiopathic thrombocytopenic purpura. (1983) (5)
A Novel Approach for Minimal Residual Disease Detection in Childhood T-Cell Lymphoblastic Lymphoma (T-LL): A Children’s Oncology Group Report. (2007) (5)
Role of minimal residual disease evaluation in leukemia therapy (2008) (5)
A novel λ integrase-mediated seamless vector transgenesis platform for therapeutic protein expression (2018) (5)
Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia (2013) (5)
Flow-Cytometry—Based Studies of Minimal Residual Disease in Children with Acute Lymphoblastic Leukemia (2003) (5)
Engineering of Natural Killer Cells for Clinical Application. (2020) (5)
Genetic Engineering and Significant Ex-Vivo Expansion of Cord Blood Natural Killer Cells: Implications for Post-Transplant Adoptive Cellular Immunotherapy (2008) (5)
Highly Sensitive Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia Using Next-Generation Sequencing of Immunoglobulin Heavy Chain Variable Region (2011) (5)
Flow cytometric immunophenotyping of acute lymphoblastic leukemia: is the time ready for consensus the guidelines? (2002) (5)
The developmental stages of the human T cell receptors: a review. (1989) (5)
Relevance of monoclonal antibodies in the diagnosis of unusual T-cell acute lymphoblastic leukaemia. (2009) (5)
Late Relapses of Childhood T-ALL Are Frequently Second T-ALL. (2007) (4)
Fas activates NF-kappaB and induces apoptosis in T-cell lines by signaling pathways distinct from those induced by TNF-alpha. (1997) (4)
Phase I study of expanded natural killer cells in combination with cetuximab for recurrent/metastatic nasopharyngeal carcinoma (2022) (4)
Development of an Off-the-Shelf Chimeric Antigen Receptor (CAR)-T Cell Therapy for T-Cell Acute Lymphoblastic Leukemia (T-ALL) without Gene Editing (2022) (4)
Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia. (2010) (4)
Acute Megakaryoblastic Leukemia (AMKL) in Children without Down Syndrome. (2009) (4)
No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy (2019) (4)
Therapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia. (2009) (4)
Immunophenotyping in haematological diagnosis. (1990) (4)
Expression of T Cell Receptor Associated Proteins During Human T Cell Development (1989) (4)
Detection of minimal residual disease in acute lymphoblastic leukemia (2011) (3)
Tumor pathological and immunological changes in HER2+ metastatic breast cancer (MBC) following trastuzumab combined with expanded and activated autologous natural killer (NK) cell infusion. (2019) (3)
Normal and aberrant T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. (1993) (3)
A First-in-Human Study of Autologous T Lymphocytes with Antibody-Dependent Cell Cytotoxicity (ADCC) in Patients with B-Cell Non-Hodgkin Lymphoma (NHL) (2016) (3)
Immune-complexes (IC) in idiopathic neutropenia. (2009) (3)
The origin of B-chronic lymphocytic leukaemia (B-CLL) and its relationship to hairy cell leukaemia (HCL). (1985) (3)
APAAP IMMUNOPHENOTYPING OF HAEMATOLOGICAL MALIGNANCIES (1986) (3)
96 – Childhood Leukemia (2014) (2)
Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia. (2009) (2)
Overcoming Chemotherapy Resistance in Childhood Acute Lymphoblastic Leukemia by Targeting Ion Channels. (2009) (2)
FLT3-Targeted Therapy Selectively Kills MLL-Rearranged Infant and Childhood ALL Blasts In Vitro and in Vivo. (2004) (2)
Expanded Natural Killer Cells for Cellular Therapy of Acute Myeloid Leukemia. (2007) (2)
Development of Anti-CD3 Chimeric Antigen Receptor (CAR)-T Cells for Allogeneic Cell Therapy of Peripheral T-Cell Lymphoma (PTCL) (2022) (2)
Characterization of CD 34 + , CD 13 + , CD 33 — cells , a rare subset of immature human hematopoietic cells (2002) (2)
Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order (2012) (2)
Abstract B03: A phase I study of cetuximab followed by activated and expanded NK cells for refractory nasopharyngeal cancer (2020) (2)
Corrigendum to "Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo". (2015) (1)
L-Serine Produced by Mesenchymal Cells in the Bone Marrow Microenvironment Is a Trophic Factor for Hematopoietic Progenitor Cells. (2005) (1)
Monoclonal Antibody BI-3C5 Reacts Specifically with M1/M2-Acute Myeloid Leukaemias and Most Non-B Non-T Acute Lymphocytic Leukaemias, and Recognises A Small Population of Immature Cells in Normal Bone Marrow (1985) (1)
Minimal residual disease in hematologic malignancies. (1994) (1)
Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104 (2010) (1)
Hospital results of Total Therapy Study XIIIB at St Jude Children's Research Improved outcome for children with acute lymphoblastic leukemia: (2013) (1)
Genetic Modification of Natural Killer Cells for Leukemia Therapies (2007) (1)
Mesenchymal Cells Determine the Response of Acute Lymphoblastic Leukemia Cells to L-Asparaginase. (2006) (1)
Phenotypic and functional heterogeneity of T lineage cells: the relevance of studies on normal lymphopoiesis for leukemia diagnosis and detection of minimal residual disease (1988) (1)
Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia (2008) (1)
Development of B cell subpopulations in humans and its relevance to malignancy. (1985) (1)
Response: Genes associated with response to therapy in childhood acute lymphoblastic leukemia (2008) (1)
Adoptively Transferred Expanded Natural Killer Cells Inhibit Myeloma Tumor Growth In Vivo. (2009) (1)
A Novel Method for Propagating Primary Natural Killer (NK) Cells Allows Highly Efficient Expression of Anti-CD19 Chimeric Receptors and Generation of Powerful Cytotoxicity Against NK-Resistant Acute Lymphoblastic Leukemia Cells. (2004) (1)
Microenvironment and Immunology T Lymphocytes Expressing a CD 16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing (2013) (1)
Monitoring minimal residual disease in pediatric hematologic malignancies. (2007) (1)
Abstract 3148: Implication of highly cytotoxic natural killer cells for esophageal cancer treatment (2015) (1)
Cancer Therapy : Preclinical 2 B 4 ( CD 244 ) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells (2009) (1)
Clofarabine treatment of KMT2Ar infantile patients with acute lymphoblastic leukemia in St. Jude Total Therapy Study 16 (2022) (1)
Corrigendum to "Insulin-like Growth Factor-binding Protein-7 (IGFBP7): A Promising Gene Therapeutic for Hepatocellular Carcinoma (HCC)". (2015) (1)
Stimulation with K562 Cells Transfected with 4-1BBL and IL-15 Expands and Activates Natural Killer (NK) Cells with Specific Cytotoxicity for Multiple Myeloma (MM). (2005) (1)
Clofarabine-Based Chemotherapy for KMT2Ar Infantile Acute Lymphoblastic Leukemia (2021) (1)
Flow cytometric diagnosis and classification of childhood leukemia in developing countries (2000) (1)
Abstract 3512: Expanded human regulatory iNKT cells exhibit direct cytotoxicity against hematolymphoid tumor targets (2012) (1)
expressing membrane-bound interleukin-15 Autonomous growth and increased cytotoxicity of natural killer cells (2014) (0)
Characterization of a Murine Monoclonal Antibody Specific for Early Lymphohemopoietic Cells (1983) (0)
Use of haplo-identical activated natural killer cells (NK) for patients with refractory hematological malignancies (2013) (0)
Abstract 4356: Cytotoxicity of the anti-CD22 immunotoxin HA22 against pediatric acute lymphoblastic leukemia (ALL) (2010) (0)
Systemic Exposure to Dexamethasone and Asparaginase Affects Risk of Relapse in Children with Acute Lymphoblastic Leukemia (2011) (0)
RIZZO MEMORIAL GRANT (2006) (0)
Protection of CML Progenitors from Bcr-Abl Tyrosine Kinase Inhibitor Mediated Apoptosis by the Bone Marrow Stromal Microenvironment. (2007) (0)
Genetic Polymorphisms in the Promoter Region of the beta-2 Adrenergic Receptor Are Associated with the Early Response of Acute Lymphoblastic Leukemia to Chemotherapy. (2004) (0)
Significant Ex-Vivo Expansion of Cord Blood (CB) Natural Killer (NK) Cells and Concomitant Decrease in CB T-Cells by Genetically Reengineered K562 Cells (K562-mbIL15-41BBL) (2009) (0)
childhood acute lymphoblastic leukemia A set of genes that regulate cell proliferation predict treatment outcome in (2013) (0)
Pharmacodynamics inChildhood Acute Lymphoblastic Leukemia (2001) (0)
5-azacytidine induction of human fetal hemoglobin. Authors' reply (2008) (0)
Phase Ib/II trial of expanded and activated autologous natural killer (NK) cells with trastuzumab (Tras) in refractory HER2+ metastatic breast cancer (MBC). (2016) (0)
Inhibition of Class I PI3K Isoforms Restores the Sensitivity of Acute Myelogenous Leukemia Cells to Multi-Tyrosine Kinase Inhibitors in the Bone Marrow Microenvironment. (2009) (0)
NK cells for cancer immunotherapy (2020) (0)
Acute tubular necrosis associated with mTOR inhibitor therapy : a real entity biopsy-proven (2013) (0)
Cell cycle analysis of normal and malignant lymphoid cells. (1990) (0)
Microenvironmental Factors Determine the Sensitivity of Acute Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors. (2008) (0)
T CELL RECEPTOR-DEFICIENT CHIMERIC ANTIGEN RECEPTOR T-CELLS AND METHODS OF USE THEREOF (2019) (0)
OP10 AML in children: treatment approach in St. Jude (2007) (0)
Autologous Activated and Expanded Natural Killer Cells Destroy Multiple Myeloma Clonogenic Tumor Cells through NKG2D and Its Ligands (2015) (0)
Killer Immunoglobulin-Like Receptor Ligand (KIR-L) Mismatched Natural Killer (NK) Cells for Relapsed Myeloma (2005) (0)
MYELOID NEOPLASIA Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identi ﬁ es polymorphisms associated with outcome in AML patients (2013) (0)
Genome-wide association study identiﬁes germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia (2012) (0)
Interleukin-2 Gene Transduction in Human Natural Killer Cells Augments Their Survival and Anti-Leukemic Capacity (2008) (0)
1 MINIMAL RESIDUAL DISEASE-GUIDED THERAPY IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (2017) (0)
Monoclonal antibody bi 3c 5 of use in the classification of acute leukemias (1985) (0)
Flow Cytometric Analysis of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia (2003) (0)
203 Hypoxic Leukemic Microenvironment and its Targeting by the Hypoxia-Activated Prodrug PR-104 (2011) (0)
Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy (2013) (0)
Autologous Activated and Expanded Natural Killer Cells Are Safe and Clinically Actives in Multiple Myeloma (2015) (0)
Without Its Cytoplasmic Domain orPro-B Cells Expressing Human CD 38 With CD 38-Mediated Signaling Events in Murine (1999) (0)
Body Mass Index Is Not Associated with Early Treatment Response or Clinical Outcome in Children with Acute Lymphoblastic Leukemia (2015) (0)
Cytokine Induced Killer (CIK) Cells Transduced with an Anti-CD19 Chimeric Receptor Containing 4-1BB Acquire Powerful Anti-Leukemic Activity. (2006) (0)
leukemia progenitors Growth requirements and immunophenotype of acute lymphoblastic (2011) (0)
Sustained Expansion of Human Natural Killer Cells for Leukemia Therapy. (2006) (0)
A Macromolecular Signaling Complex Formed by CXCR4, VLA4 and hERG1 K + Channels Mediates Bone Marrow-Induced Chemo-Resistance in Childhood Acute Lymphoblastic Leukemias: Shortcoming Effects of hERG1 Channels Inhibitors. (2008) (0)
Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple Myeloma (2008) (0)
Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country (2017) (0)
signals and induces specific killing of leukemic cells Genetic modification of primary natural killer cells overcomes inhibitory (2013) (0)
Abstract PR-2: Characterization of germline genetic variants underlying racial disparities of childhood leukemia outcome (2009) (0)
Autologous Activated and Expanded Natural Killer Cells Kill Clonogenic Myeloma Cells: A New Therapeutic Option for Multiple Myeloma (2014) (0)
Increasing the antineoplastic potential of natural killer cells with a chimeric receptor activated by NKG2D ligands (2013) (0)
Monoclonal antibodies for diagnosis and therapy of lymphoproliferative diseases. (1990) (0)
Monoclonal Antibodies for Bone Marrow Purging before Transplantation: A Brief Review (1988) (0)
Immunotherapy of B Cell Malignancies Using Transiently Redirected Cytotoxic T Cells. (2007) (0)
Abstract CT146: Prognostic and therapeutic significance of leukemia subtypes in the context of risk-directed therapy based on minimal residual disease levels in pediatric acute lymphoblastic leukemia (2021) (0)
Interferon 3' Inhibits Apoptotic Cell Death in B Cell Chronic Lymphocytic Leukemia (2003) (0)
Development of Effective Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma with CD19-Specific Cytotoxic T Cells. (2004) (0)
Genome-Wide Expression Profiling and Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia. (2005) (0)
The expression of T-cell receptor-associated proteins in normal and leukaemic immature T cells. (1989) (0)
Purging in autologous bone marrow transplantation (ABMT): Importance of antigen density on leukaemia blasts for the efficiency of complement-mediated cytolysis (1986) (0)
Monitoring of Minimal Residual Disease to Guide Therapy of Acute Lymphoblastic Leukemia (2014) (0)
Stages of T-cel l Receptor Protein Expression in T-cel l Acute Lymphoblastic Leukemia (2003) (0)
Reply to the letter from von Stackelberg et al (2004) (0)
Cell therapy (DC, Treg, NKT) (PP-040) (2010) (0)
Mutations in the Human (cid:108) 5/14.1 Gene Result in B Cell Deﬁciency and Agammaglobulinemia (1997) (0)
Cytarabine-Induced Gene Expression Signatures in AML Patients and Its Association with Clinical Outcome. (2012) (0)
for Bone Marrow Purging in Acute Lymphoid Leukemia (2011) (0)
Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma (2011) (0)
N-Cadherin-Mediated Microenvironmental Interactions Protect CML Stem Cells from Imatinib Mediated Apoptosis. (2008) (0)
Leukaemia and lymphoma treatment with autologous bone marrow transplantation: preclinical studies. (1988) (0)
Expanded Human INKT Cells Exhibit Th2 Polarization and Direct Cytotoxicity Against Hematolymphoid Tumor Targets (2011) (0)
A Highly Efficient, Clinically Applicable Transfection Method to Redirect the Specificity of Immune Cells and Enhance Their Anti-Tumor Capacity (2008) (0)
Diagnostic Techniques in Hematological Malignancies: Acute lymphoblastic leukemia (2010) (0)
Pharmacodynamics in Childhood Acute Lymphoblastic Leukemia (2001) (0)
Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy (2010) (0)
Genetic variations in cytarabine pathway genes as determinants of outcome in acute myeloid leukemia. (2013) (0)
Adoptive CAR T Cell Therapy Targeting GD2-Positive Cancers (2016) (0)
215 Ex vivo expanded NK cells up-regulate natural cytotoxicity receptors able to mediate autologous melanoma cell killing (2017) (0)
Multiple Infusions of Autologous Activated and Expanded Natural Killer Cells: A New Therapeutic Option for Multiple Myeloma (2015) (0)
hERG1 channels and is overcome by hERG1 blockers Chemotherapy resistance in acute lymphoblastic leukemia requires (2011) (0)
Antigen Expression and Proliferative Activity during B and T Cell Development (1988) (0)
METHODS: ORIGINAL ARTICLE A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus (2013) (0)
Immunodeficiencies: Comparisons and Contrasts (2009) (0)
Childhood Leukemias: Minimal residual disease (2006) (0)
Reverse-engineering flow-cytometry gating strategies for phenotypic labelling and high-performance cell sorting (2018) (0)
Stages of T-cell receptor protein expression in T-ALL. (1991) (0)
Human multipotent mesenchymal stromal cells (MSCs) induce proliferation of allogeneic peripheral blood mononuclear cells. (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dario Campana?

Dario Campana is affiliated with the following schools:

Dario Campana's Academic­Influence.com Rankings

Why Is Dario Campana Influential?

Dario Campana's Published Works

Published Works

What Schools Are Affiliated With Dario Campana?

Dario Campana's AcademicInfluence.com Rankings